4-异丙基-1,3-二氢-2H-苯并咪唑-2-酮 | 103151-02-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 4-异丙基-1,3-二氢-2H-苯并咪唑-2-酮
• 英文名称: 4-isopropyl-1,3-dihydro-benzimidazol-2-one
• 英文别名: 4-Isopropyl-1,3-dihydro-benzimidazol-2-on；4-isopropyl-1H-benzo[d]imidazol-2(3H)-one；4-propan-2-yl-1,3-dihydrobenzimidazol-2-one
• CAS: 103151-02-6
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: AQSMGQMCZYALLB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-异丙基乙酰苯胺 在 N-溴代丁二酰亚胺(NBS) 、 硝酸 作用下， 生成 4-异丙基-1,3-二氢-2H-苯并咪唑-2-酮
  参考文献：
  名称：

  Synthesis of Some Substituted Benzoxazolones

  摘要：

  DOI：

  10.1021/ja01540a038

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• CHEMICAL COMPOUNDS
  申请人：ASTRAZENECA AB

  公开号：US20190177338A1

  公开（公告）日：2019-06-13

  The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

  该规范涉及到式（I）的化合物及其药用盐。该规范还涉及用于它们制备的过程和中间体，含有它们的药物组合物以及它们在治疗细胞增殖性疾病中的用途。
• SOMATOSTATIN MODULATORS AND USES THEREOF
  申请人：Crinetics Pharmaceuticals, Inc.

  公开号：US20180016252A1

  公开（公告）日：2018-01-18

  Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

  本文描述了一些肽类调节剂化合物，制备这类化合物的方法，包含这类化合物的药物组合物和药物，以及利用这类化合物治疗需要调节生长抑素活性的疾病、症状或疾病的方法。
• METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND
  申请人：Miki Takashi

  公开号：US20120123122A1

  公开（公告）日：2012-05-17

  The present invention relates to a method for manufacturing a boronic acid ester compound, characterized by reacting an aryl halide compound and a diboron ester compound in the presence of a nitrogen-containing organic base, a nickel catalyst, a phosphine compound and a solvent. According to the manufacturing method of the present invention, even if a nickel catalyst is used as the catalyst, a desired boronic acid ester compound can be obtained in a sufficiently high yield. Furthermore, even if aryl chloride or aryl bromide having relatively low price and low reactivity, was used as the aryl halide compound, a desired boronic acid ester compound can be obtained in a sufficiently high yield.

  本发明涉及一种制备硼酸酯化合物的方法，其特征在于在氮含有机碱、镍催化剂、膦化合物和溶剂的存在下，将芳基卤化物化合物和二硼酯化合物反应。根据本发明的制造方法，即使使用镍催化剂作为催化剂，也可以获得所需的硼酸酯化合物，产率足够高。此外，即使使用价格较低且反应性较低的芳基氯化物或芳基溴化物作为芳基卤化物化合物，也可以获得所需的硼酸酯化合物，产率足够高。
• NEW BICYCLIC COMPOUNDS AS PI3-K AND MTOR INHIBITORS
  申请人：Pastor Fernández Joaquin

  公开号：US20130131057A1

  公开（公告）日：2013-05-23

  There is provided compounds of formula (I), wherein A 1 , A 4 , A 4a , A 5 , B 1 , B 1a , B 2 , B 2a , B 3 , B 3a , B 4 , B 4a and R 3 have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PI3-K and/or mTOR) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease.

  提供了式（I）的化合物，其中A1、A4、A4a、A5、B1、B1a、B2、B2a、B3、B3a、B4、B4a和R3在描述中给出了它们的含义，以及其药用可接受的酯、酰胺、溶剂合物或盐，这些化合物在治疗需要抑制蛋白质或脂质激酶（例如 PI3-K 和/或 mTOR）的疾病中是有用的，特别是在癌症或增殖性疾病的治疗中。